RxDoctor Payments Data

Vipul Joshi, MD

Rheumatology · Brandon, FLNPI 1003868993

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $25,844 of the $42,600 with a category attached, or 60.7%. 37 manufacturers reported payments, led by Amgen at 47.0% of the total. Reporting peaked in 2019 at $16,530 and has fallen 72.3% since, to $4,573 in 2025.

$42,600in general payments, 2019–2025

Across 1,500 payments — averaging $28.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$20K
  • UCB, Inc.$4K
  • Novartis$3K
  • AbbVie$2K
  • AstraZeneca$2K
  • Merck$1K
  • plus $10K from 31 others
$3,066,182in research payments, 2019–2025

Across 485 payments — averaging $6322.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$696K
  • AbbVie$523K
  • Novartis$455K
  • Astrazeneca UK Limited$357K
  • GSK$325K
  • UCB SA$284K
  • plus $426K from 10 others

What the payments were for

  • Consulting fees$9,67523%
  • Speaking & faculty fees$2,7006%
  • Travel & lodging$4,18010%
  • Food & beverage$25,84461%
  • Education$2010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,600 in reported general payments places this provider in the 85th percentile of 453 rheumatology providers in Florida.

See all rheumatology providers in Florida

Medicare billing

Part B allowed, 2024
$8,118,707
Medicare patients
1,030
Services billed
659,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept17$156,596
Humira PenAdalimumab15$118,543
Pregabalin122$4,015
Tramadol Hcl284$2,273
Hydroxychloroquine Sulfate23$1,209
MethotrexateMethotrexate Sodium13$273
Duloxetine Hcl13$170
Clonazepam12$27

Paid to pharmacies, not to this prescriber.

Other rheumatology in Brandon

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →